newheader.jpg

Search CHI's Network

 


Conference Menu

Overview
Agenda-Day One
Agenda-Day Two
Complimentary Invitation
Download PDF
Register
Poster
Hotel & Travel
Press Pass
Request Brochure
Order CD
Send to a Colleague
Upcoming Conferences

Corporate Sponsor:

 

Corporate Support:

 

Lead
Sponsoring Publication:

 

Sponsoring Publications:

 
Web Partners:


Held immediately following the
Fifth Annual BioMEMS and Nanotech World, August 16-17, 2004

DAY 2


Thursday, August 19, 2004


8:00 Poster & Exhibit Viewing, Coffee

NEXT GENERATION DETECTION

8:30 Chairperson’s Remarks
Dr. Nitish V. Thakor, Professor of Biomedical Engineering and Electrical Engineering, Johns Hopkins University School of Medicine

8:35 Identifying Biomarkers from Host Response using a Human Whole Blood Model
Dr. Brett Chromy, Deputy Group Leader, Biodefense, Lawrence Livermore National Laboratory 
Although detection capabilities focusing on pathogen DNA signatures have been successful, our efforts in presymptomatic detection rely on characterization of host immune response to provide biomarkers for next-generation detection. While cell culture and animal models are also being investigated, we have utilized a human whole blood model to define host response following exposure to , Y. pestis, and near neighbors of Y. pestis (Y. enterocolitica and Y. pseudotuberculosis) using advanced proteomic technologies including 2-D DIGE, SELDI-MS and protein arrays. Our results reveal shared host expression changes indicative of a common immune response; however, distinct pathogen-specific proteomic differences have been identified, representing potential blood biomarkers for early detection of pathogen exposure in support of biodefense preparedness.

9:05 Real-Time Detection of Microbial Contamination
Dr. Linda S. Powers, Director, National Center for the Design of Molecular Function, Professor of Electrical and Computer Engineering, Professor of Biological Engineering, Adjunct Professor of Physics, Utah State University 
Using a unique combination of leading-edge technologies, we have developed a hand-held, continuous, real-time monitor for detection of microbial contamination together with microbe capture technology for identification of the microbial contamination. Detection of microbial contamination is based upon intrinsic fluorescence of the components of cells and spores. Identification is achieved by molecular recognition of pathogenesis using iron acquisition and eukaryotic receptor adhesion strategies as well as peptide ligands produced by combinatorial chemistry. Together these are capable of statistically sampling the environment for pathogens [including bacteria, fungi, spores and viruses] and exotoxins, identifying the specific pathogens/exotoxins, and determining cell viability. This system is sensitive enough to detect very low levels [~20 cells/cm² on surfaces or ~100 cells/50 mL solution] of microbes. These technologies for the detection and identification of microbial presence have been tested and characterized on surfaces, such as foods, glass, plastics, cloth, stainless steel, etc., as well as in water/liquids and air. This system has been demonstrated in water systems, air handling systems, and at SuperBowl XXXVIII [2004].

9:35 A Novel Method For Massively Parallel, Whole Genome Sequencing
Dr. Kenton L. Lohman, Senior Director, Technology and Application Assessment, 454 Life Sciences 
One of the most informative molecular tools for comparing or identifying specific organisms is nucleic acid sequence. Real- time amplification and hybridization chip technologies rely to a great degree on having a priori knowledge of the identity of the organism or marker being targeted. Unfortunately, there are many organisms that have limited published sequence data and verifying the uniqueness of specific gene targets has routinely been found to have exceptions in strain identification. Whole genome sequencing would alleviate these exceptions and provide a wealth of additional information. Sequencing as a diagnostic tool has been out of reach due to excessive time to result and cost constraints. We have developed an instrument and reagent system that massively parallel-processes all the functions of genomic sequencing including sample preparation, amplification, sequencing and data analysis. Our current throughput for re-sequencing allows the generation of a whole bacterial genome sequence within a few days by one researcher on a single instrument. Quality of the reads reaches gold standard 1/10000 error rates. We are currently scaling the system to be able to handle mammalian genomes. This technology will open the door to whole genome sequencing as a rapid, and inexpensive tool for species and strain comparison and identification.

10:05 Coffee Break, Poster & Exhibit Viewing

10:45 Electrochemiluminescence Methods in the Detection of Select Agents
Dr. Jeff Rossio, Associate Director, Biodefense Research & Development, Biodefense, BioVeris Corp. 
BioVeris Corporation develops and markets biological detection systems, based on its proprietary BV™ Technology, which provides a unique combination of sensitivity, reliability, speed and flexibility. These systems are used in multiple applications, including clinical diagnostics, pharmaceutical research and development, life science research, biodefense testing and industrial food testing. Numerous tests have been developed based on BV technology, including those for the detection of: Botulinum neurotoxins, SEA/SEB, Ricin, Botulinum toxins and Anthrax Lethal Factor Protease Assays, E. coli O157, Salmonella, Cryptosporidium, among others. 

11:15 Computational Intelligence for Pathogen Identification
Dr. Jerome Braun, Staff, Biodefense Systems, MIT Lincoln Laboratory 
An approach for automatic identification of multiple pathogens will be presented. The approach is applicable to a wide range of pathogens. Integrating molecular aspects with computational intelligence aspects, the proposed approach forms a powerful basis for multi-pathogen biodefense detection and identification.

11:45 Panel Discussion with the Speakers

12:15 Lunch on your own 

1:30 Technology Workshop

Sponsored by:

The RAZOR: A Handheld PCR Identifier; Developed for Mobile Field Testing by US Special Forces.
Dr. Randy Rasmussen, COO, Todd Ritter, CDO, Idaho Technology Inc.
During this workshop, Idaho Technology Inc. will demonstrate the RAZOR™ Instrument; a 9.1 lbs handheld, field hardened, bio-threat identifier for the US DoD. The workshop will include a complete set-up and run of the system demonstrating it’s ease-of-use and speed to results. It tests up to twelve samples in less than 22 minutes, and performs five runs on one battery charge. The RAZOR uses proven freeze-dried reagents in a thin-film plastic pouch format as reaction containers. Samples are loaded into the pouches with syringes, requiring no measurement and minimal operator setup. The instrument automatically determines positives and negatives and displays results on an LCD interface. Specificity and sensitivity are comparable to Idaho Technology’s successful R.A.P.I.D.® system and freeze-dried reagent kits. The RAZOR was tested and validated by the US DoD and has recently been released for use to First Responders, Homeland Defense and Security Personnel.

 

THERAPEUTIC DEVELOPMENTS IN BIODEFENSE

2:00 Chairperson’s Remarks
Dr. Arthur M. Krieg, Chief Scientific Officer, Coley Pharmaceuticals

Featured Presentation
2:05 Bioterrorism Preparedness, What it Means for Public Health in the U.S
Dr. Lisa Rotz, Deputy Director of the Bioterrorism Preparedness and Response Program (BPRP), National Center for Infectious Diseases, Centers for Disease Control and Prevention
This presentation will update conference attendees on current national public
health bioterrorism preparedness efforts and the improvements made within
the public health system as a result of these activities.

2:35 NIAID Biodefense Resources and Sponsored Proteomics Research: Bead Based Proteome Screens
Dr. Timothy A. Gondré-Lewis, Program Officer, Immunoregulation Section, Basic Immunology Branch, Biodefense, National Institute of Allergy and Infectious Diseases
This presentation will highlight NIAID funded research resources available to the biodefense research community, and recent research from the Biodefense Proteomics Collaboratory Project, David G. Gorenstein, Principal Investigator. Using in vitro enzymatic combinatorial selection and split-synthesis methodologies, this group has synthesized oligonucleoside phosphorodithioate aptamer (thioaptamer) libraries in which only one thioaptamer species is attached to each bead. These thioaptamer beads have been used for fluorescence-based high throughput flow cytometric analysis of NF-kB proteins and show diagnostic promise in proteome screens for immunomodulatory or pathogen proteins of biodefense concern.

3:05 Targeting Toll-like Receptors to Induce Innate and Adaptive Immunity Against Biothreat Agents 
Dr. Arthur M. Krieg
Toll-like receptors (TLRs) are a family of immune defense proteins that appear to have evolved to detect molecules that are present in certain general classes of pathogens, but are not present in our own cells. TLRs can be activated with synthetic ligands to induce protective innate and adaptive immune responses. Several TLR ligands are currently in various stages of preclinical and clinical development, and have shown some activity in various biodefense models. CpG oligos are TLR9 ligands that have proven particularly active for inducing nonspecific or specific immunity to several CDC Category A and B agents in animal models. In human clinical trials CpG 7909 appears to be a promising vaccine adjuvant and CpG 10101 shows evidence of activity for nonspecific immunoprophylaxis of infection. 

3:35 Refreshment Break, Poster & Exhibit Viewing

4:05 Selecting and Evolving Antibodies for Potent Neutralization of Botulinum Neurotoxins
Dr. James D. Marks, Professor, Anesthesia and Pharmaceutical Chemistry, and Program Member, Comprehensive Cancer Center, University of California, San Francisco
The botulinum neurotoxins (BoNTs) are one of the most feared biothreat agents. We have been generating and characterizing panels of antibodies to botulinum neurotoxin type A (BoNT/A) to: 1) determine the optimal antibody characteristics for potent toxin neutralization; and 2) to develop antibody for treatment and prevention of botulism. Extensive characterization of a panel of antibodies to (BoNT/A) indicates that no single antibody can significantly neutralize BoNT/A. Combining two or three antibodies to the cellular receptor binding domain of BoNT/A, however (oligoclonal antibody) leads to potent toxin neutralization. Using molecular evolution, we have determined the impact of affinity on BoNT neutralization for single monoclonal antibodies and monoclonal antibody combinations. The results provide insights into the major mechanisms by which antibodies synergize to neutralize toxin.

4:35 Oligoclonics: Mixtures of Recombinant Human Antibodies Produced by Clonal Cell Lines for Improved Biological Efficacy
Dr. Ton Logtenberg, Chief Executive Officer, Merus BV
The natural immune response yields polyclonal antibodies that collectively mediate the efficient elimination of pathogens. Therapeutic monoclonal antibodies recapitulate only a fraction of the natural immune response, thereby losing the superior efficacy of polyclonal antibodies. Merus has developed technology for the high level expression of multiple human antibodies in clonal cell lines. This technology sets the stage for the identification of mixture of antibodies with superior biological efficacy for the elimination of viral and bacterial pathogens.

5:05 Panel Discussion with the Speakers

5:30 Close of Day Two


Call for Sponsors and Exhibitors
Showcase your company's expertise, brand your solutions and develop revenue opportunities with qualified decision-makers by becoming an Exhibitor or Sponsor of BioMEMS and NANOtech World 2004! Contract exhibit booth space by June 15, 2004 and you will save $300! If you want to discuss sponsoring or exhibiting at BioMEMS and NANOtech 2004, please contact Angela Parsons at 781-972-5467 or aparsons@healthtech.com

foot.jpg


Cambridge Healthtech Institute| Beyond Genome | Bio-IT World | Biomarker World Congress | Digital Healthcare & Productivity |
 Discovery On Target | Bio-IT World Conference & Expo  | Insight Pharma Reports | Molecular Medicine Tri-Conference | PEGS
PepTalk
| Pharma WeekWorld Pharmaceutical Congress

Your  Life Science Network

Cambridge Healthtech Institute  |  250 First Avenue  |  Suite 300   |   Needham,  MA  02494
Phone: 781-972-5400  |   Fax: 781-972-5425
chi@healthtech.com